Phospholipase A2 Isoforms in Lung Immunity and Respiratory Infections: Potential Targets for Next-Generation Therapy
Shweta Joshi1, Kelly Walter2, Dante Hamiel2
1Institute of Health Management Research, IIHMR University, Prabhu Dayal Marg, Jaipur 302029, India.
International Journal of Molecular Sciences
|June 12, 2026
Summary
This review explores how phospholipase A2 (PLA2) enzymes impact immune responses during lung infections. Understanding PLA2
Area of Science:
- Immunology
- Lipid Metabolism
- Respiratory Medicine
Background:
- Lipid metabolism critically regulates host immunity, but its interaction with immune responses is not fully understood.
- The phospholipase A2 (PLA2) enzyme family plays a key role in lipid signaling and is involved in various physiological and pathological processes.
Purpose of the Study:
- To elucidate the immunomodulatory role of lung-enriched phospholipase A2 (PLA2) pathways in respiratory infections.
- To review the biological functions of PLA2 isoforms in the context of host-pathogen interactions and inflammation.
Main Methods:
- Literature review of current knowledge on PLA2 isoforms and their functions.
- Analysis of PLA2's role in regulating immune responses during respiratory infections.
- Exploration of PLA2's involvement in host-pathogen interactions and inflammatory outcomes.
Main Results:
- PLA2 enzymes cleave phospholipids, releasing mediators that influence inflammation and host defense.
- Airway-expressed PLA2 isoforms can either protect against or exacerbate pathogenesis during respiratory infections.
- PLA2 activity influences immune cell influx, vascular permeability, and tissue damage in the airways.
Conclusions:
- PLA2 enzymes are key regulators of immune responses in the lungs during infections.
- Understanding PLA2's dual role is crucial for developing therapeutic strategies against respiratory diseases.
- Further research into PLA2 regulation and function can illuminate host-pathogen dynamics.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:42Phosphoinositides and PIPs
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.